PPIDT00387
Drug Information
| Name | Fremanezumab |
|---|---|
| Sequence | EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWISWVRQAPGKGLEWVAEIRSESDASATHYAEAVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLAYFDYGLAIQNYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPSSIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB14041 |
| Type | biotech |
| Indication | Fremanezumab is indicated for the preventative treatment of migraine in adults.[L11749] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Subcutaneous |
225 mg/1.5mL
|
| Injection, solution | Parenteral; Subcutaneous |
225 MG
|
| Injection, solution | Subcutaneous |
225 mg
|
| Injection, solution | Subcutaneous |
225 mg/1.5mL
|
| Solution | Subcutaneous |
225 mg / 1.5 mL
|
| Solution | Subcutaneous |
225.00 mg
|
| Injection, solution | — |
225 mg/1.5ml
|